Oncology Letters · 2017 · 12 citations · 16 references
MedicineOncologyPathologyMetastasisMolecular OncologyTumor ProgressionCancer BiomarkersCancer Molecular PathologyGastric CancerMolecular Tumor ProfilingTumor MarkersBiomarkers Of Gastric CancerCancer Metastasis BiomarkersImmunohistochemical BiomarkersLymph Node Metastasis PrognosisMetastatic BiomarkersMolecular Prognostic MarkersPrognostic BiomarkersTissue Microarrays
MDM2 binding protein (MTBP) has been revealed to be involved in cancer progression and metastasis. However, the role and clinical implication of MTBP expression in gastric cancer (GC) remains poorly understood. The present study aimed to investigate the clinicopathological significance of MTBP and the prognostic determinant in GC. The expression level of MTBP was examined in cancerous and matched adjacent noncancerous gastric mucosa tissues by reverse transcription-quantitative polymerase chain reaction and western blotting. MTBP expression levels were evaluated by immunohistochemical analysis of tissue microarrays for 352 patients, and association between the expression levels and prognosis in patients with GC were investigated. Kaplan-Meier analysis and Cox's regression models were used to investigate the associations between MTBP expression and prognosis of GC patients. The results of the present study revealed decreased MTBP mRNA (P=0.005) and protein (P=0.001) expression levels in tumor tissue compared with in matched adjacent normal tissue mucosa. MTBP expression level in GC was associated with gender (P=0.026), lymph node metastasis (P<0.001), distant metastasis (P=0.026) and pathological tumor-node-metastasis stage (P<0.001). Kaplan-Meier survival analysis demonstrated that patients with high MTBP expression levels exhibited longer survival times compared with patients with low MTBP expression levels. The multivariate logistic regression analysis revealed that MTBP was independently associated with the presence of lymph node [OR, 0.282; 95% confidence interval (CI), 0.161-0.494; P<0.001] and distant metastasis (OR, 0.365; 95% CI, 0.138-0.965; P=0.042). Furthermore, the multivariate Cox analysis revealed that low MTBP expression level was significantly associated with longer overall survival time and was recognized as an independent prognostic factor of patient's survival. MTBP expression level was significantly associated with progression and metastasis in GC, suggesting that MTBP may be used as a predictive marker for patient prognosis of GC.
16
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text
TNM Classification of Malignant Tumors
Darryl Carter · The American Journal of Surgical Pathology · 1998 · 6.4K citations
Farin Kamangar, Graça M. Dores, William F. Anderson · Journal of Clinical Oncology · 2006 · 3.5K citations
Henk H. Hartgrink, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet · 2009 · 890 citations · Full text
Tomoo Iwakuma, Guillermina Lozano · PubMed · 2003 · 391 citations